{"id":296424,"date":"2025-03-13T00:00:00","date_gmt":"2025-03-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0019-2022-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-03-31T10:26:40","modified_gmt":"2026-03-31T10:26:40","slug":"cutrcg0019-2025-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights-multiple-sclerosis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0019-2025-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights-multiple-sclerosis\/","title":{"rendered":"Multiple Sclerosis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Multiple Sclerosis (EU5)"},"content":{"rendered":"<p>Numerous disease-modifying therapies (<abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s) have entered the multiple sclerosis (<abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most recently, <span class=\"abbreviation-guard\">TG<\/span> Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody and Sandoz launched Tyruko, the first biosimilar for <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>. Given the rapid pace of expansion in the <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> market, developers of both current and emerging <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s must continually reassess their products\u2019 differentiation and positioning in this highly competitive space. This report will explore neurologists\u2019 perceptions of established and recently launched <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s, their prescribing habits in today\u2019s market, and anticipated changes in brand usage as <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr> choices expand\u2014and further complicate\u2014prescribing decisions.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How are different <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> subpopulations (i.e., clinically isolated syndrome, relapsing-remitting <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>, secondary-progressive <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>, and primary-progressive <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>) treated?<\/li>\n<li>How do product shares differ across lines of therapy? Which high-efficacy therapies (e.g., Ocrevus) are factoring into early-line treatment decisions?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients have experienced a relapse or disability progression in the past year? What percentage have nonrelapsing <abbr data-abbreviation-entity=\"4962\" title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr>?<\/li>\n<li>How have neurologists\u2019 prescribing changed in the past year, and why? What further changes do they expect within the next year?<\/li>\n<li>What are neurologists\u2019 opinions on the newest entrants in the <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> market, and how are they incorporating these <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s in the treatment paradigm?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Through survey data from <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand&#8217;s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n<p><strong>Markets Covered: <\/strong>France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p><strong>Key drugs covered: <\/strong>Ocrevus, Kesimpta, Briumvi, Tysabri, Tyruko, fingolimod, teriflunomide, Tecfidera, platform injectable therapies<\/p>\n<p><strong>Key companies:<\/strong><strong> <\/strong>Biogen, Novartis, Roche, Sandoz \/ Polpharma Biologics, <span class=\"abbreviation-guard\">TG<\/span> Therapeutics \/ Neuraxpharm<\/p>\n<p><strong>Key analyses:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296424","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296424\/revisions"}],"predecessor-version":[{"id":413442,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296424\/revisions\/413442"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}